All In Biotech

Drug Trial Radar · NCT00540722

Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

A Phase 2 Study of R-(-)-Gossypol (Ascenta's AT-101) in Recurrent Glioblastoma Multiforme

Last checked: Nov 19, 2026Latest source record: Aug 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

56

Actual

Start

Jan 2008

Primary completion

Jun 2012

Study completion Jun 2012

Sponsor

Sponsor type
NIH
First posted
Oct 8, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial is studying how well gossypol works in treating patients with progressive or recurrent glioblastoma multiforme. Gossypol may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Adult Giant Cell Glioblastoma
  • Adult Glioblastoma
  • Adult Gliosarcoma
  • Recurrent Adult Brain Tumor

Interventions

  • R-(-)-gossypol acetic acidDrug

    Given PO

  • laboratory biomarker analysisOther

    Correlative studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: 4.5 years

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Moffitt Cancer Center

    Tampa, Florida

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.